regena-logo

Microenvironment Repair Therapy | p53:
Restoring Balance, Rejuvenating Health

Harnessing the Body’s Natural Healing Power

Understanding the Microenvironment

The cellular microenvironment is a complex system crucial for cell function and tissue regeneration. Factors like aging, disease, and injury can disrupt this balance, leading to impaired healing. 

The Role of p53

p53 is a tumor suppressor protein that safeguards cells and prevents cancer. It monitors cells for damage and initiates repair or programmed cell death when necessary. 

Microenvironment Repair Therapy and p53

Regena’s Microenvironment Repair Therapy, featuring Gendicine, restores balance and promotes healing by targeting the cellular microenvironment.  

Potential Benefits of Microenvironment Repair Therapy

  • Enhanced tissue repair and regeneration  
  • Improved immune function  
  • Reduced risk of age-related diseases  
  • Improved overall health and well-being 

Proven Safety and Efficacy in Clinical Trials

Gendicine has been extensively evaluated in clinical trials, demonstrating its safety and efficacy in treating various cancers. These trials have shown promising results across a range of cancer types, including:

Head and Neck Cancer

In a study involving 688 patients, Gendicine, in combination with chemotherapy and/or radiotherapy, showed a high overall response rate. The complete response rate was 30%, and the partial response rate was 54%

Gynecological Cancers

Gendicine has also been explored in the treatment of cervical and ovarian cancers, which have high rates of p53 mutations. In a clinical trial of 317 patients with cervical cancer, the combination of Gendicine with chemotherapy or radiotherapy resulted in a 47% complete response rate and a 44% partial response rate.

Lung Cancer

p53 mutations are prevalent in lung cancer, particularly non-small cell lung cancer. Clinical trials have investigated the use of Gendicine in combination with radiotherapy and chemotherapy, showing improved outcomes compared to standard therapies alone.

Liver Cancer

Gendicine has been studied in combination with transcatheter hepatic artery chemoembolization (TACE) for the treatment of liver cancer. Results indicated that the combination therapy was safe and effective, with a 12% complete response rate and a 61% partial response rate.

The Future of Cell Microenvironment Therapy with p53

future-p53

Building on the successes of Gendicine, the future of cell microenvironment therapy with p53 holds immense promise. Ongoing research is focused on further enhancing its therapeutic potential and expanding its applications. Key areas of future development include:

Overcoming Resistance

Investigating strategies to address potential resistance to Gendicine, such as modifying the adenoviral vector or exploring alternative delivery methods.

Optimizing Combination Therapies

Conducting further research to refine the combination of Gendicine with chemotherapy, radiotherapy, and other treatment modalities, aiming to maximize efficacy and minimize side effects.

Developing New Formulations

Exploring controlled-release and extended-release formulations of Gendicine to optimize drug delivery and therapeutic outcomes.

Expanding Clinical Applications

Investigating the efficacy of Gendicine in a wider range of cancers and exploring its potential in personalized medicine.